Mian, Hira http://orcid.org/0000-0003-1584-1067
McCurdy, Arleigh http://orcid.org/0000-0002-8809-4368
Giri, Smith
Grant, Shakira http://orcid.org/0000-0002-8481-3046
Rochwerg, Bram
Winks, Erica
Rosko, Ashley E.
Engelhardt, Monika http://orcid.org/0000-0003-0405-1676
Pawlyn, Charlotte http://orcid.org/0000-0002-7190-0028
Cook, Gordon http://orcid.org/0000-0003-1717-0412
Jackson, Graham
Bringhen, Sara http://orcid.org/0000-0003-4539-6363
Facon, Thierry
Larocca, Alessandra
Zweegman, Sonja
Wildes, Tanya M.
Funding for this research was provided by:
Dr. HM is the recipient of a Research Early Career Award from Hamilton Health Sciences Foundation
Article History
Received: 26 September 2022
Revised: 15 December 2022
Accepted: 19 December 2022
First Online: 5 January 2023
Competing interests
: HM: Consultancy/Honoraria fees from GSK, Janssen, BMS/Celgene, Forus therapeautics, Amgen, Takeda, Sanofi; Research Funding from Janssen. AM: Honoraria/Advisory fees: GSK, Janssen, BMS/Celgene, Forus therapeutics, Amgen, Takeda, Sanofi; Research funding: BMS/Celgene. SG: Research funding from PackHealth CareVive and Sanofi. Honorarium from Carevive and OncLive. SJG: Supported by National Comprehensive Institute Grant No. (5-K12-CA120780-13; PI: William Kim) and National Institute on Aging Grant No. (1 R03 AG074030-01; PI: Shakira Grant). BR: None. EW: None. AER: Honoraria from Onclive, CurioScience, Medscape, I3Health. ME: None. CP: Honoraria from BMS/Celgene, Janssen, Sanofi; Consultancy fees from Abbvie, BMS/Celgene, Janssen, Sanofi. GC: No relevant COI. GJ: Honoraria from Takeda, BMS, Pfizer, Amgen J and J, GSK, and Oncopeptides. SB: Honoraria from Celgene, Amgen, Janssen, and Bristol Myers Squibb; Consultancy fees from Janssen, Takeda, Celgene, and Bristol Myers Squibb; Board of Directors or Advisory Committees for Celgene, Amgen, Janssen, GlaxoSmithKline, Sanofi. TF: No relevant COI. AL: Honoraria from and served on the advisory boards for Janssen-Cilag, Bristol Myers Squibb, Amgen, Takeda, Oncopeptides, GlaxoSmithKline, Sanofi, and Karyopharm. SZ: Research funding from Janssen, Takeda; Advisory Board for Janssen, Takeda, BMS, Oncopepties, Sanofi. TMW: Consulting fees from Carevive Systems, Sanofi; Research funding from Janssen.